RU58841 is a research chemical that was designed and tested in clinical trials to fight androgenic alopecia. Despite its intentions for “research use only”, this drug is used by many hair loss sufferers looking to take their fight against androgenetic alopecia to new levels. It’s also tested by people who cannot tolerate finasteride due to its side effects.
- The in vitro evidence suggests that RU58841 can bind to androgen receptors, therefore preventing testosterone and dihydrotestosterone from exerting their effects. Furthermore, it was found to be even more potent than flutamide at this.
- The in vivo (in monkeys) evidence suggests that RU58841 can exert its effect specifically at the tissue in which it was applied even at doses of up to 100 µg, without any effects on cells, hormone levels, or tissues outside of the area the treatment was applied to. Furthermore, a topical application of 5% showed a dramatic increase in hair regrowth over 4 months of usage, without any subsequent effect on serum hormone levels.
- Some preclinical studies have found that RU58841 may show antagonistic agonism – meaning that the enzymes blocked by a specific drug may show greater activity after usage has stopped – however, it is not known whether this effect occurs in humans.
- There have been two clinical trials completed by the company developing RU58841, however, the results of these were never published, which is unusual and suggest that either RU58841 did not produce appreciable hair regrowth results in humans or it potentially wasn’t safe in humans.
- Our experience tracking members: by itself, RU58841 alone is not enough to improve hair loss outcomes.